Researchers have used plants to produce virus-like particles (VLPs) of the dengue virus in a potential first step towards novel vaccines against the growing threat.
The team in the group of Professor George Lomonossoff at the John Innes Centre in collaboration with Leaf Expression Systems produced VLPs of dengue virus serotype 1, one of four serotypes of the virus.
Dengue is a pathogenic mosquito-borne virus belonging to the Flaviviridae family that causes 390 million infections per year. A safe, effective vaccine is needed because of ongoing questions about existing vaccine candidates. .
Researchers used a variety of tobacco (Nicotiana benthamiana) to transiently express the VLPs using technology pioneered at the John Innes Centre by Professor Lomonossoff. After extraction and purification, the VLPs were shown to stimulate an immune response to the virus in experiments on mice.
“This is the first of what would be many steps along the path towards making dengue vaccines in plants,” said corresponding author Dr Hadrien Peyret of the John Innes Centre.
Using the metabolism of plants to produce these valuable molecules potentially offers an affordable and low-tech solution to vaccine development.
VLPs are authentic mimics of the virus containing the protein coat but without the infectious material. This as the basis for a vaccine is enough to train the immune system without causing an infection.
Virus-like particles for non-enveloped viruses can, in most cases, be readily produced in plants using transient expression technology. It was also known that VLPs of the enveloped influenza virus could be produced in plants using this technology.
However, influenza VLPs seemed to be an exception, for this type of virus with a protective lipid outer-envelope. Until this study, there were no published examples of VLPs purified from plants for other enveloped viruses.